In Vivo Efficacy Models for Autologous CAR-T: IND-Enabling Studies

Executive Summary: Designing predictive in vivo efficacy models for autologous CAR-T therapies requires a scientific strategy that moves beyond standardized templates. The primary objective is to generate a robust data package under GxP conditions that characterizes anti-tumor activity, potential toxicities like cytokine release syndrome (CRS), and cellular persistence. This approach is fundamental for constructing a successful Investigational New Drug (IND) submission to the US FDA and is informed by our work with partners like our partners on complex therapeutic platforms.

Tailored Model Selection for Efficacy and Safety

The selection of an appropriate in vivo model is the foundational step. The decision between a xenograft model, using human tumor cell lines in immunodeficient animals, and a syngeneic model in immunocompetent animals has significant implications for the data generated.

Key design elements include:

• Tumor Model: Orthotopic implantation is often preferred over subcutaneous models to better replicate the tumor microenvironment and metastatic potential.

• Efficacy Endpoints: Tumor burden is typically monitored via bioluminescence imaging (BLI) or caliper measurements, providing quantitative data on anti-tumor activity.

• Safety Assessment: Models must be designed to detect potential liabilities, including CRS, neurotoxicity, and on-target/off-tumor effects through clinical observations and terminal histology.

Our >100,000 sq ft facility is equipped to handle these complex, long-term studies under the GxP conditions required for regulatory submission. These preclinical programs are a core component of our broader Cell and Gene Therapy CRO Services.

Applying Learnings from Adjacent Therapeutic Platforms

While CAR-T presents unique challenges, principles from other advanced therapies can inform study design. The long-term evaluation of vector persistence and safety in nonhuman primate models, for instance, provides a framework for assessing CAR-T durability (PMID: 33609733). Similarly, work demonstrating enhanced function of engineered proteins in preclinical models reinforces the importance of linking molecular design to in vivo therapeutic effect (PMID: 25023731). These cross-modality insights strengthen the rationale behind the preclinical data package.